{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'treatment administration. These subjects will subsequently be followed for an additional', '20 weeks (i.e., 22 weeks after the final dose of study treatment) during a Safety Follow-Up', 'Period (see Section 5.4.3).', 'All subjects will be reminded of study contact information to report potential SAEs and are', 'to inform the Investigator if they experience such events during the Safety Follow-Up Period', '(Section 7.4.5.4).', '5.3', 'Selection of Study Population', 'The study population will consist of subjects with moderately to severely active RA who', 'previously completed 24 weeks of double-blind treatment in one of the core CREDO studies.', 'This is an international study, and it is expected that approximately 1880 subjects will be', 'randomized at approximately 250 sites across Russia, Belarus, the US, Europe, UK, Asia,', 'and Latin America.', '5.3.1', 'Inclusion Criteria', 'Subjects may be enrolled in the study only if they meet all of the following criteria:', '1. Subject must be willing and able to sign informed consent', '2. Subject must have completed the 24-week double-blind Treatment Period in 1 of the', '3 core studies (CL04041022, CL04041023, or CL04041025).', '3. Subject must have maintained their stable dose (and route) of MTX 15 to 25 mg/week (or', '>10 mg/week if there is documented intolerance to higher doses) during the core study', 'and plan to maintain the same dose and route of administration for >12 additional weeks.', '4. Subjects must be willing to take folic acid or equivalent throughout the study.', '5.3.2', 'Exclusion Criteria', 'Subjects who meet any of the following criteria will not be eligible for the study:', '1. Subject with any medically important condition in the core study (e.g., clinically', 'significant laboratory values, frequent AEs or SAEs, infection SAEs, and/or other', 'concurrent severe and/or uncontrolled medical condition) which would make this subject', \"unsuitable for inclusion in the OLE study in the Investigator's judgement.\", '2. Subject has evidence of active TB', '3. Subject with a positive or repeated indeterminate interferon-gamma release assay (IGRA)', 'result at Week 22 of the core study', 'Amendment 2: 06 March 2019', '53', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Subjects may be enrolled in the OLE study if they fulfill all 3 of the following criteria', 'prior to the first dose of study treatment:', 'a.', 'Active TB is ruled out by a certified TB specialist or pulmonologist who is', 'familiar with diagnosing and treating TB (as acceptable per local practice);', 'b. The subject starts prophylaxis for latent TB infection (LTBI) according to', 'country-specific/Centers for Disease Control and Prevention (CDC) guidelines', '(see Appendix 4 [Section 13.4]) (treatment with isoniazid for 6 months is not an', 'appropriate prophylactic regime for this study and it should not be used); and', 'c.', 'The subject is willing to complete the entire course of recommended LTBI', 'therapy (see Appendix 4 [Section 13.4]).', '4. Subject has planned surgery during the first 12 weeks of the OLE study', '5. Female subjects who are pregnant or lactating, or who are planning to become pregnant', 'during the study or within 6 months of the last dose of study treatment', '6. Female subjects of childbearing potential (unless permanent cessation of menstrual', 'periods, determined retrospectively after a woman has experienced 12 months of natural', 'amenorrhea as defined by the amenorrhea with underlying status [e.g., correlative age]', 'or', '6 months of natural amenorrhea with documented serum follicle-stimulating hormone', 'levels >40 mIU/mL and estradiol <20 pg/mL) who are not willing to use a highly', 'effective method of contraception during the study and for at least 6 months after the last', 'administration of study treatment', 'OR', 'Male subjects with partners of childbearing potential not willing to use a highly effective', 'method of contraception during the study and for at least 3 months after the last', 'administration of study treatment.', 'Highly effective contraception is defined as:', 'Female sterilization surgery: hysterectomy, surgical bilateral oophorectomy (with or', 'without hysterectomy) or tubal ligation at least 6 weeks prior to the first dose of study', 'treatment in the core study', '- In the case of oophorectomy alone, only when the reproductive status of the', 'woman has been confirmed by documented follow-up hormone level assessment', 'Amendment 2: 06 March 2019', '54', 'Confidential']\n\n###\n\n", "completion": "END"}